David H. Talbot
|
David Talbot is a Managing Director and Registered Representative with Pickwick Capital Partners. He has extensive Wall Street and buy-side experience in the healthcare industry, especially in the diagnostics sector where he currently focusses on proprietary new technologies such as in vitro blood testing for early detection, outpatient and home patient monitoring systems, and web-enabled digital diagnostics.
Prior to joining Pickwick, Mr. Talbot was a leading HC analyst at several research firms including F. Eberstadt, William D. Witter, Drexel Burnham Lambert, Needham, and Arnhold S. Bleichroeder and Company. He also has over a decade of buy-side experience including the founding and management of the Healthcare Reform Investment Trust, which was listed on the London Stock Exchange. Mr. Talbot has been ranked in the Institutional Investor All-Star research poll in two healthcare categories – medical device and hospital sectors – for eleven consecutive years. Mr. Talbot has an MBA from The Kellogg Graduate School of Management, an AB in American Civilization from Brown University, and he is a U.S. Navy veteran. |
|
